Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF

ConclusionsOur study is the first to analyse the potential role of echocardiography and, in particular, of RV dysfunction, measured by TAPSE, in predicting Sac/Val maximum dose tolerability. Therefore, patients with RV dysfunction (baseline TAPSE<16  mm, in our cohort) might benefit from a different strategy to titrate Sac/Val, such as starting from the lowest dose and/or waiting for a more extended period of observation before attempting with the higher doses.

Source: ESC Heart Failure - June 15, 2022 Category: Cardiology Authors: Valeria Visco, Ilaria Radano, Alfonso Campanile, Amelia Ravera, Angelo Silverio, Daniele Masarone, Giuseppe Pacileo, Michele Correale, Pietro Mazzeo, Giuseppe Dattilo, Francesco Giallauria, Alessandra Cuomo, Valentina Mercurio, Carlo Gabriele Tags: Original Article Source Type: research